Metabolomics is rapidly gaining adoption in drug development, largely due to its ability to discover and validate biomarkers that can help support key decisions throughout the process, from discovery through clinical trials.
Download this article to learn how two leading biotech companies, Seres Therapeutics and Siolta Therapeutics, harnessed the power of metabolomics to guide drug development decision-making and advance their programs to the next phase of development.
Offered Free by: Metabolon
See All Resources from: Metabolon
